1. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
- Author
-
Vrdoljak E, Boban M, Omrcen T, Hrepic D, Fridl-Vidas V, and Boskovic L
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms mortality, Breast Neoplasms pathology, Capecitabine, Deoxycytidine administration & dosage, Deoxycytidine therapeutic use, Female, Fluorouracil administration & dosage, Fluorouracil therapeutic use, Humans, Middle Aged, Mitomycin administration & dosage, Neoplasm Metastasis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives, Mitomycin therapeutic use
- Abstract
Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m² day 1 and capecitabine 1000 mg/m² twice daily, days 1-14. Combination chemotherapy was administered for a maximum six cycles, single-agent capecitabine could be continued until progressive disease or unacceptable toxicity. Thirty patients were included, objective response rate was 65.5%. After a median follow-up of 18.5 months, median time to progression was 8.5 months and median overall survival was 29.8 months. The main adverse events were thrombocytopenia, pneumonitis and hemolytic uremic syndrome. Our data suggest that first-line capecitabine and MMC has good antitumor activity in MBC, but is associated with MMC-specific toxicity.
- Published
- 2011
- Full Text
- View/download PDF